Andrew D. Ashe J.D.
Net Worth

Last updated:

What is Andrew D. Ashe J.D. net worth?

The estimated net worth of Mr. Andrew D. Ashe J.D. is at least $5,966,861 as of 14 May 2024. He owns shares worth $3,836,101 as insider and has received compensation worth at least $2,130,760 in Verve Therapeutics, Inc..

What is the salary of Andrew D. Ashe J.D.?

Mr. Andrew D. Ashe J.D. salary is $532,690 per year as Pres & Chief Operating Officer in Verve Therapeutics, Inc..

How old is Andrew D. Ashe J.D.?

Mr. Andrew D. Ashe J.D. is 58 years old, born in 1967.

What stocks does Andrew D. Ashe J.D. currently own?

As insider, Mr. Andrew D. Ashe J.D. owns shares in one company:

Company Title Shares Price per share Total value
Verve Therapeutics, Inc. (VERV) Pres & Chief Operating Officer 342,509 $11.2 $3,836,101

What does Verve Therapeutics, Inc. do?

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

VERV logo
VERV
Verve Therapeutics, Inc.
$11.2

Andrew D. Ashe J.D. insider trading

Verve Therapeutics, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 76,000 $6.26 $475,760
Option
Stock Option (right to buy) 33,749 $1.48 $49,949
Option
Stock Option (right to buy) 10,835 $2.87 $31,096
Option
Common Stock 51,203 $1.39 $71,172
Option
Stock Option (right to buy) 51,203 $1.39 $71,172
Option
Common Stock 10,835 $2.87 $31,096
Option
Common Stock 33,749 $1.48 $49,949
Purchase
Common Stock 4,000 $32.11 $128,420

Verve Therapeutics key executives

Verve Therapeutics, Inc. executives and other stock owners filed with the SEC: